Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT01614509

Branch Retinal Vein Occlusion

COMPLETED NA

Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

NCT00970957

Macular Edema Retinal Vein Occlusion

COMPLETED PHASE3

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

NCT01178697

Central Retinal Vein Occlusion

UNKNOWN PHASE2

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

NCT04812977

Central Retinal Vein Occlusion With Macular Edema

COMPLETED NA

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

NCT01044329

Branch Retinal Vein Occlusion

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema Central Retinal Vein Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab and triamcinolone

three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Macular edema secondary to central retinal vein occlusion
* BCVA worse than 20/40
* Central macular \>250 mc with OCT

Exclusion Criteria

* Diabetic retinopathy or other retinopathy
* Media opacity that does not allow following
* steroid responder
* diagnosed glaucoma or IOP \> 21 mmHg

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Asociación para Evitar la Ceguera en Mexico IAP